This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Avidia Inc. (protein therapeutics) raised $28.5mm through the sale of Series B preferred shares. Morgenthaler Ventures led the round and was joined by other new investors TPG Ventures, MedImmune Ventures, and Amgen Ventures, and returning backers Alloy Ventures, Maxygen (which created Avida in 2003 as a spin-off), Avidia scientific founder Willem Stemmer, and other individuals.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?